Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cetrorelix Acetate

FDA-approved product (powder, subcutaneous), marketed as Cetrorelix Acetate, Cetrotide.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cetrorelix Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Ovulation Inhibition
  • Positive regulation of ovulation

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Anti-gonadotropin-releasing hormones
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cetrorelix Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cetrorelix Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Use of Antagonist Versus Agonist GnRH in Oocyte Recipient Endometrium Preparation

    NCT00633347 · start 2007-01

    Registered record
    Registry ID
    NCT00633347
    Conditions
    Infertility
    Interventions
    Antagonist GnRH Cetrotide; Agonist GnRH Acetate Triptoreline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-01
    Completion
    2009-10
    Enrolment
    570

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility
    InterventionAntagonist GnRH Cetrotide; Agonist GnRH Acetate Triptoreline
    PhasePhase 4
    Registry statusCompleted

  • A Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy, Safety and Duration of Effect of a Single Administration of Various Doses of Cetrorelix SR in Subjects With Histologically Confirmed Endometriosis

    NCT00244452 · start 2005-11

    Registered record
    Registry ID
    NCT00244452
    Conditions
    Endometriosis
    Interventions
    Cetrorelix
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-11
    Completion
    2006-09
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    InterventionCetrorelix
    PhasePhase 2
    Registry statusCompleted

  • Pregnancy Outcomes With a GnRH Antagonist Protocol Versus GnRH-Agonist Protocol in ICSI Cycles

    NCT00485537 · start 2005-09

    Registered record
    Registry ID
    NCT00485537
    Conditions
    Infertility
    Interventions
    oocyte retrieval and ICSI procedure
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-09
    Completion
    2006-12
    Enrolment
    2,005

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility
    Interventionoocyte retrieval and ICSI procedure
    PhaseNot applicable
    Registry statusCompleted

  • A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation

    NCT00298025 · start 2003-09

    Registered record
    Registry ID
    NCT00298025
    Conditions
    Infertile Women Undergoing Assisted Reproductive Technology (ART)
    Interventions
    Cetrotide®; Antagon ™; Recombinant human follicle stimulating hormone (r-hFSH); Human Menopausal Gonadotropin (hMG); Recombinant Human Choriogonadotropin (r-hCG)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-09
    Completion
    2004-05
    Enrolment
    185

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertile Women Undergoing Assisted Reproductive Technology (ART)
    InterventionCetrotide®; Antagon ™; Recombinant human follicle stimulating hormone (r-hFSH); Human Menopausal Gonadotropin (hMG) +1 more
    PhasePhase 4
    Registry statusCompleted

  • GnRH Agonist and Antagonists in an Oocyte Donation Program

    NCT00505817

    Registered record
    Registry ID
    NCT00505817
    Conditions
    Effect of Two Protocols of Ovarian Stimulation on Oocyte Quality
    Interventions
    Cetrorelix and Leuprolide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEffect of Two Protocols of Ovarian Stimulation on Oocyte Quality
    InterventionCetrorelix and Leuprolide
    PhasePhase 4
    Registry statusCompleted